Cardiff Oncology, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
July 9, 2020
VIA EDGAR
United States
Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Abby Adams
Re: | Cardiff Oncology, Inc. | |
Form S-1 | ||
File No. 333-239464 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Cardiff Oncology, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, July 10, 2020, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you, | ||
CARDIFF ONCOLOGY, INC. | ||
By: | /s/ Mark Erlander | |
Name: Mark Erlander | ||
Title: Chief Executive Officer |
-1-